The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy (RC).

[1]  M. Remzi,et al.  Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes. , 2019, European urology.

[2]  Anirban P. Mitra,et al.  Molecular markers in bladder cancer , 2008, Current opinion in urology.

[3]  M. Babjuk,et al.  A systematic review and meta‐analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens , 2018, BJU international.

[4]  S. Shariat,et al.  Accuracy and prognostic value of variant histology and lymphovascular invasion at transurethral resection of bladder , 2018, World Journal of Urology.

[5]  S. Shariat,et al.  Characteristics and clinical significance of histological variants of bladder cancer , 2017, Nature reviews. Urology.

[6]  J. Witjes,et al.  MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER , 2016 .

[7]  Maximilian Burger,et al.  EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. , 2017, European urology.

[8]  A. Briganti,et al.  The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder , 2016, Nature Reviews Urology.

[9]  I. Christensen,et al.  uPAR Expression Pattern in Patients with Urothelial Carcinoma of the Bladder – Possible Clinical Implications , 2015, PloS one.

[10]  A. Vickers,et al.  Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. , 2015, European urology.

[11]  I. Christensen,et al.  Urokinase-type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial carcinoma of the bladder. , 2015, Urologic oncology.

[12]  Yair Lotan,et al.  Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. , 2015, European urology.

[13]  Nicholas D James,et al.  Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. , 2014, European urology.

[14]  M. Rubin,et al.  Frequent truncating mutations of STAG2 in bladder cancer , 2013, Nature Genetics.

[15]  F. Montorsi,et al.  Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. , 2013, Cancer epidemiology.

[16]  Y. Lotan,et al.  Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. , 2012, European urology.

[17]  C. Dinney,et al.  Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort , 2011, BJU international.

[18]  H. Grossman,et al.  Age and body mass index are independent risk factors for the development of postoperative paralytic ileus after radical cystectomy. , 2010, Urology.

[19]  M. Milowsky,et al.  Bladder cancer in the elderly. , 2009, Urologic oncology.

[20]  C. Roehrborn,et al.  Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. , 2009, European urology.

[21]  Aamir Ahmad,et al.  Evolving role of uPA/uPAR system in human cancers. , 2008, Cancer treatment reviews.

[22]  Yair Lotan,et al.  Nomograms Provide Improved Accuracy for Predicting Survival after Radical Cystectomy , 2006, Clinical Cancer Research.

[23]  Yair Lotan,et al.  Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. , 2006, The Journal of urology.

[24]  S. Loening,et al.  In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder. , 2004, Oncology reports.

[25]  C. Roehrborn,et al.  Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy. , 2004, The Journal of urology.

[26]  S. Shariat,et al.  Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. , 2003, Urology.

[27]  T. Wheeler,et al.  Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. , 2003, Urology.

[28]  G. Steineck,et al.  Expression of UPA and UPAR is associated with the clinical course of urinary bladder neoplasms , 2002, International journal of cancer.

[29]  M. Kattan,et al.  E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. , 2001, The Journal of urology.

[30]  A. Sumiyoshi,et al.  The content of urokinase‐type plasminogen activator antigen as a prognostic factor in urinary bladder cancer , 1992, International journal of cancer.